Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2018

Open Access 01-08-2018 | Research Article

Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey

Authors: Raymond Li, Colin Curtain, Luke Bereznicki, Syed Tabish Razi Zaidi

Published in: International Journal of Clinical Pharmacy | Issue 4/2018

Login to get access

Abstract

Background Under-reporting of adverse drug reactions (ADRs) by healthcare professionals is prevalent worldwide. Community pharmacists are the most frequently visited healthcare professional and are well placed to document ADRs as a part of their routine practice. Objective To measure community pharmacists’ knowledge and perspectives towards ADR reporting and their reporting practices. Setting Community pharmacists in the New South Wales, Queensland, Victoria and Tasmania, Australia. Method A survey tool consisting of 28 items was developed, piloted and validated by a panel of expert reviewers. The final anonymised survey was distributed online to community pharmacists. Exploratory factor analysis and Cronbach’s alpha were used to measure the validity and reliability of the tool, respectively. Non-parametric statistical tests were used to analyse knowledge, perspectives and ADR reporting practices. Main outcome measures: Knowledge, perceived importance, enablers and barriers to reporting ADRs. Results The survey tool showed acceptable validity and reliability. A total of 232 respondents completed the survey. The median knowledge score was 5 out of 10 (interquartile range, 2). Less than a third of respondents (31.0%) reported sufficient knowledge and training on ADR reporting. Only 35.3% of pharmacists reported at least one ADR in the previous 12 months. Non-reporting pharmacists were more likely to report lack of time as a barrier (P < 0.001), conversely they were more likely to report if the practice was remunerated (P = 0.007). Conclusion Under-reporting of ADRs by community pharmacists is highly prevalent. Initiatives to educate and train them on ADR reporting and simplifying the reporting process may improve reporting practices.
Appendix
Available only for authorised users
Literature
3.
go back to reference Food and Drugs Administration. Department of Health and Human Services. 21CFR314.80—post-marketing reporting of adverse drug experiences volume 5 updated April 1999. Food and Drugs Administration. Department of Health and Human Services. 21CFR314.80—post-marketing reporting of adverse drug experiences volume 5 updated April 1999.
5.
go back to reference Furburg CD, Bertram Pitt. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205–7.CrossRef Furburg CD, Bertram Pitt. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205–7.CrossRef
6.
go back to reference Pillans PI, Ghiculescu RA, Lampe G, Wilson R, Wong R, Macdonald GA. Severe acute liver injury associated with lumiracoxib. J Gastroenterol Hepatol. 2012;27:1102–5.CrossRef Pillans PI, Ghiculescu RA, Lampe G, Wilson R, Wong R, Macdonald GA. Severe acute liver injury associated with lumiracoxib. J Gastroenterol Hepatol. 2012;27:1102–5.CrossRef
9.
go back to reference Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2016;29(5):385–96.CrossRef Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2016;29(5):385–96.CrossRef
10.
go back to reference Classen D, Pestotnik S, Evans RS, Burke JP. Computerised surveillance of adverse drug reactions in hospitalised practice. JAMA. 1991;266:2847–51.CrossRef Classen D, Pestotnik S, Evans RS, Burke JP. Computerised surveillance of adverse drug reactions in hospitalised practice. JAMA. 1991;266:2847–51.CrossRef
12.
go back to reference Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:191.CrossRef Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:191.CrossRef
13.
go back to reference Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, et al. Incidence and costs of adverse drug reactions during hospitalisation. Computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000;22:161–8.CrossRef Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, et al. Incidence and costs of adverse drug reactions during hospitalisation. Computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000;22:161–8.CrossRef
14.
go back to reference Roughhead L, Semple S, Rosenfeld E. Australian Commission on safety and quality in healthcare. In: Roughhead L, Semple S, Rosenfeld E, editors. Literature review: medication safety in Australia. Sydney: ACSQHC; 2013. Roughhead L, Semple S, Rosenfeld E. Australian Commission on safety and quality in healthcare. In: Roughhead L, Semple S, Rosenfeld E, editors. Literature review: medication safety in Australia. Sydney: ACSQHC; 2013.
18.
go back to reference Xu H, Wang Y, Liu N. A hospital based survey of healthcare professionals in the awareness of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2009;18:624–30.CrossRef Xu H, Wang Y, Liu N. A hospital based survey of healthcare professionals in the awareness of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2009;18:624–30.CrossRef
19.
go back to reference Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19:217–22.CrossRef Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19:217–22.CrossRef
21.
go back to reference Toklu HZ, Uysal MK. The knowledge and perspective of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci. 2008;30:556–62.CrossRef Toklu HZ, Uysal MK. The knowledge and perspective of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci. 2008;30:556–62.CrossRef
22.
go back to reference Vessal G, Mardani Z, Mollai M. Knowledge, perspectives, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci. 2009;31:183–7.CrossRef Vessal G, Mardani Z, Mollai M. Knowledge, perspectives, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci. 2009;31:183–7.CrossRef
23.
go back to reference Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, et al. Community pharmacist’s knowledge, behaviours and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J. 2014;22:411–8.CrossRef Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, et al. Community pharmacist’s knowledge, behaviours and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J. 2014;22:411–8.CrossRef
24.
go back to reference Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster randomized trial among pharmacists in Portugal. Drug Saf. 2008;31:335–44.CrossRef Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster randomized trial among pharmacists in Portugal. Drug Saf. 2008;31:335–44.CrossRef
25.
go back to reference Kelly M, Kaye KI, Davis SR, Shenfield GM. Factors influencing adverse drug reaction reporting in New South Wales teaching hospitals. J Pharm Pract Res. 2004;34:32–5.CrossRef Kelly M, Kaye KI, Davis SR, Shenfield GM. Factors influencing adverse drug reaction reporting in New South Wales teaching hospitals. J Pharm Pract Res. 2004;34:32–5.CrossRef
26.
go back to reference Nita Y, Batty KT, Plumridge RJ. Adverse drug reaction reporting: perspectives of australian hospital pharmacists and doctors. J Pharm Pract Res. 2005;35:9–14.CrossRef Nita Y, Batty KT, Plumridge RJ. Adverse drug reaction reporting: perspectives of australian hospital pharmacists and doctors. J Pharm Pract Res. 2005;35:9–14.CrossRef
32.
go back to reference Kaiser HF. The Varimax criterion for analytic rotation in factor analysis. Psychometrika. 1958;23(3):187–200.CrossRef Kaiser HF. The Varimax criterion for analytic rotation in factor analysis. Psychometrika. 1958;23(3):187–200.CrossRef
34.
go back to reference Varallo FR, Guimaraes S, Abjaude S, De Carvalho Mastroianni P. Causes for the underreporting of adverse drug events by healthcare professionals: a systematic review. Rev Esc Enferm. 2014;48:739–47.CrossRef Varallo FR, Guimaraes S, Abjaude S, De Carvalho Mastroianni P. Causes for the underreporting of adverse drug events by healthcare professionals: a systematic review. Rev Esc Enferm. 2014;48:739–47.CrossRef
38.
go back to reference Hobbs T. Therapeutics goods administration—access all areas: empowering patient care using TGA initiatives. Presented at Pharmacy Australia Congress; 2014. Hobbs T. Therapeutics goods administration—access all areas: empowering patient care using TGA initiatives. Presented at Pharmacy Australia Congress; 2014.
39.
go back to reference Van de Mortel TF. Faking it: social desirability response bias in self-report research. Aust J Adv Nurs. 2008;25:40–8. Van de Mortel TF. Faking it: social desirability response bias in self-report research. Aust J Adv Nurs. 2008;25:40–8.
Metadata
Title
Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey
Authors
Raymond Li
Colin Curtain
Luke Bereznicki
Syed Tabish Razi Zaidi
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0700-2

Other articles of this Issue 4/2018

International Journal of Clinical Pharmacy 4/2018 Go to the issue